Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
amoxicillin + clavulanic acid + lactobacillus acidophilus
- Development stage
- Unknown
- Lead developer
- Avogadro
- Modality
- Live Biotherapeutic Products → Microbiome Therapeutics, Small Molecules
- Administration
- Oral
01
Overview
Hardclav is a combination antibiotic and probiotic formulation developed and marketed by Avogadro (Avogadro Lifesciences). It is primarily indicated for the treatment of various bacterial infections, including those of the respiratory tract, urinary tract, skin, ears, and sinuses. The formulation combines amoxicillin, a penicillin-class beta-lactam antibiotic that inhibits bacterial cell wall synthesis, with clavulanic acid (often as potassium clavulanate), a beta-lactamase inhibitor that protects amoxicillin from enzymatic degradation by resistant bacteria. In its tablet form, Hardclav also includes Lactobacillus acidophilus (lactic acid bacillus), a probiotic component that helps restore and maintain healthy intestinal microflora, thereby mitigating common antibiotic-associated gastrointestinal side effects such as diarrhea.
- Brand names
- HardclavHardclav DDSHardclav Tablet
- Other names
- amoxicillin + clavulanic acid + lactic acid bacillusamoxicillin + clavulanic acid + lactobacillusamoxycillin + clavulanic acid + lactobacillus acidophilus
02
Targets
PBP (Penicillin-binding protein family)β-lactamase
Beyond the preview
Go deeper on amoxicillin + clavulanic acid + lactobacillus acidophilus.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on amoxicillin + clavulanic acid + lactobacillus acidophilus.